Updated: FDA’s safety review on CAR-Ts culminates in new boxed warnings of secondary cancer
Published
The FDA has told Novartis, Gilead, Bristol Myers Squibb and Johnson & Johnson to add boxed warnings on the labels of six CAR-T therapies noting the risks of secondary cancer. The agency caused a stir in the CAR-T space when it revealed the safety review in November, which came as…
#fda #novartis #gilead #bristol #squibb #johnsonjohnson #scientists #clinicians #unlock